Wave Life Sciences Q3 2026 Results: Net Loss of $61.9M, Loss Widens
Wave Life Sciences reported total assets of $507.9 million as of September 30, 2026, a decrease from $638.5 million at year-end 2025, primarily driven by a reduction in cash and cash equivalents. The company transitioned a significant portion of its liquidity into marketable securities and reported 197,228,968 shares of common stock outstanding as of October 21, 2026.
- Key figure
- Net loss $61.9M